Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03835819
Title A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute

endometrial cancer


Mirvetuximab Soravtansine + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02215 United States Details
University of Massachusetts Recruiting Worcester Massachusetts 01605 United States Details
*Shaded cells indicate that there was no data available from for the field